History

Constella Group was co-founded by Donald A. Holzworth and Steven Sielkop in 1983 as Analytical Sciences, Inc. (ASI), a small statistical consulting firm. In 1995, Holzworth became sole owner of ASI and has since never wavered in his mission to build a company based on cultivating long-term customer relationships through superior quality service. Beginning with his connections at the National Institute of Environmental Health Sciences and the Centers for Disease Control and Prevention, Holzworth sought to help public-sector clients address critical health-related problems of national significance.

Constella has reached many milestones while striving to reach its vision of enhancing human health around the world, every day.

Constella won its first major contract with the CDC in 1991 and began non-drug related clinical studies, specializing in clinical laboratory performance evaluation studies. Over the next few years, the company expanded its strategic drug development work into the private sector and developed expertise in health communications, scientific peer review and information technology services. In 2001, Constella acquired United Information Systems (UIS), Inc., a private technology and health sciences company based in Bethesda, Md., gaining 150 employees and growing its science and technology services and capabilities. In 2003, Constella expanded again into the private sector, acquiring Resource Solutions, Inc., a specialty contract research organization in Research Triangle Park, N.C., with 50 employees.

In 2005, Constella expanded to working in more than 60 countries around the world with its acquisition of Futures Group. Futures Group, an international leader in creating public health and social programs for developing countries, brought Constella to the forefront of global public health issues in HIV/AIDS, TB and malaria, maternal and child health, and family planning and reproductive health. The acquisition nearly doubled Constella’s size and revenue. At the same time, Constella secured its first ever institutional equity financing. Constella used the $61 million in equity and debt capital to expand its services to public- and private-sector clients and to grow its market presence across the public health spectrum through acquisitions within the U.S. and abroad.

Just one year later, Constella completed two acquisitions—acquiring Origin Pharmaceuticals a U.K.-based full service, international contract research organization (CRO) with 100 employees, and Lineberry Research Associates, a Research Triangle Park, North Carolina-based contract research organization with 75 employees. Together, these two acquisitions have supported Constella’s goal of building a global platform to provide contract drug and device development services.

Today, Constella has more than 1,500 employees around the world dedicated toward helping people around the world live healthier, safer lives. The company has 15 offices and works in more than 60 countries around the world.